Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with induction chemotherapy, concurrent chemoradiotherapy, and maintenance for locally advanced cervical cancer
ChiCTR2200061097Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, nab-paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
camrelizumabnab-paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200061097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061097.